ArticleJournal of materials science. Materials in medicine2026
Bioinspired polymer-incorporated copper/iron nanozyme to boost cascade ROS accumulation for augmented hepatocellular carcinoma cuproptosis/ferroptosis.
Article in Journal of materials science. Materials in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC), an infamously incurable tumor, is extremely sensitive to ferroptosis, and its development is greatly aided by the glutathione (GSH) antioxidant defense system. We present a gelatin (GT)/hyaluronic acid (HA)-stabilized Copper (Cu) and Iron (Fe) nanoparticle (5CFGH NPs) for HCC therapy that uses a self-amplified dual mechanism of cuproptosis and ferroptosis. It has a Cu/Fe mass ratio of 5:5. HA in 5CFGH selectively binds to HCC cells overexpressing CD44 receptor. This enables 5CFGH to release metal ions in acidic conditions after entering cells through receptor-mediated endocytosis. In the HepG2 cell line, released Fe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.